The global clinical next-generation sequencing (NGS) market reached $2.7 billion in 2016. This market is expected to grow at a compound annual growth rate (CAGR) of 27%, from nearly $3.2 billion in 2017 to $10.5 billion by 2022.
The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents and companies. The markets for NGS-based diagnostics are given for the years 2015, 2016, 2017 and 2022.
This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the significant research initiatives that impact clinical NGS applications. The main market driving forces are also discussed.
The report examines the markets by test complexity, clinical indication and test purpose. Test complexity refers to the plex level (i.e., the number of genetic markers that can be analyzed within a sample) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics, etc.) will be in demand in the future.
The report provides market data and forecasts for NGS diagnostics by specific applications, including those for cancer, cardiovascular diseases, clinical microbiology and infectious diseases, Mendelian disorders, metabolic and immune disorders, neurological disorders, reproductive health, and transplant medicine.
Specific geographic markets are discussed, including North America, Europe, Asia-Pacific, and the rest of the world.
Industry sectors analyzed include sequencing instruments, target enrichment, informatics, clinical laboratory testing services, reproductive health diagnostics, liquid biopsy, immune sequencing, HLA typing, third generation sequencing, and direct to consumer.
More than 200 companies in the clinical NGS industry are profiled in this report.
BCC Research provides a summary of the main industry acquisitions and strategic alliances from 2015 through April 2017, including key alliance trends.
- An overview of the global market for next-generation sequencing and its emerging clinical applications.
- Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022.
- Examination of the sequencing industry structure for key market segments.
- Discussion covering the strategies employed by the main companies in the market.
- Comprehensive company profiles of major players in the field.
The growth curve in next-generation sequencing (NGS) clinical applications is approaching an upward trajectory as existing applications gain traction and new applications begin to establish a foothold in the industry.
Principal drivers of the market growth in the future clinical NGS industry include precision medicine and genomics initiatives, penetration into large market economies such as China, and emergence of highpotential applications in average risk noninvasive prenatal testing, preventive genetic screening, and early cancer detection.
Several unique aspects of NGS make it a desirable technology for clinical applications.
Since NGS platforms can sequence entire genomic regions or even entire genomes, a single test can examine hundreds or thousands of clinically important genetic variations. This means that one test can replace multiple conventional single-gene tests, providing an advantage in price and in the amount of precious sample needed for the test itself.
NGS is often more accurate and reliable than existing diagnostics. This can result in better clinical outcomes. For example, NGS can increase the pregnancy success rates for in vitro fertilization applications. Also, in rare genetic diseases, NGS can increase the success rates for determining a molecular diagnosis.
The NGS platform allows companies to expand the menu of disorders and diseases over time after initial launch of a test. This strategy has been employed in reproductive health applications, for example, launching a test to initially screen for aneuploidies, and then later expanding the test to include screening for additional genetic variants.
These features of NGS platforms provide a solid basis for the use of this technology in the clinic.
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Overview
Clinical NGS Markets
Clinical NGS Growth Driving Forces
Clinical NGS Applications
Clinical NGS Industry
Chapter 4 Technology Background
Importance of DNA
Genetic Variation and Analysis
Genetic Analysis Technologies
Sequencing in Clinical Applications
History of DNA Sequencing
Sanger Sequencing Technology
Next-Generation Sequencing Platforms
Mapping to a Reference Sequence
Clinical Sequencing Technology Challenges
Chapter 5 Clinical NGS Initiatives
Clinical Next-Generation Sequencing Projects
Actionable Genome Consortium
Cancer Moon Shoots Program
China Precision Medicine Initiative
France Genomic Medicine Plan
Metagenomics and Metadesign of Subways and Urban Biomes (MetaSub)
Million Veteran Program
National Microbiome Initiative
Chapter 6 Clinical NGS Applications
Mendelian Disorders Applications
Reproductive Health Applications
Microbiology and Infectious Disease Applications
Complex Disorders Applications
Chapter 7 Clinical NGS Industry
NGS Instrument Industry
Target Enrichment and Amplification Industry
NGS Clinical Informatics Industry
NGS Testing Services Industry
Reproductive Health Diagnostics Industry
NonInvasive Prenatal Testing Industry
Fetal Cell NIPT Industry
Liquid Biopsy Industry
Immune Sequencing Industry
HLA Typing Industry
Third-Generation Sequencing Industry
Tier 1 Companies
Tier 2 Companies
Tier 3 Companies
Direct-to-Consumer Genetic Testing Industry
Chapter 8 Acquisitions and Strategic Alliances
Chapter 9 Clinical NGS Markets
Growth Driving Forces
Clinical Sequencing Market
Clinical NGS Cancer Market
NGS Cardiology Diagnostics Markets
NGS Mendelian Disorders Diagnostics Markets
NGS Metabolic/Immune Disorder Diagnostics Markets
NGS Neurology Diagnostics Markets
Reproductive Health Markets
NGS Microbiology and Infectious Disease Diagnostic Market
Newborn Screening Market
Carrier Screening Market
Chapter 10 Patent Review
Chapter 11 Company Profiles
Clinical NGS Patents
Clinical NGS Patents by Indication
Cell-free DNA Patents
Sequencing-Related Patent Issues
10X GENOMICS, INC.
ADAPTIVE BIOTECHNOLOGIES INC.
AGILENT TECHNOLOGIES INC.
ALMAC GROUP LTD.
AMARANTUS BIOSCIENCE HOLDINGS INC.
ATHENA DIAGNOSTICS INC.
BASE4 INNOVATION LTD.
BAYLOR MIRACA GENETICS LABORATORIES INC.
BECTON, DICKINSON AND CO.
BELLWETHER BIO INC.
BERRY GENOMICS CO. LTD.
BIO-RAD LABORATORIES INC.
CAMBRIDGE EPIGENETIX LTD.
CARIS LIFE SCIENCES
CELLULAR RESEARCH INC.
CLARITAS GENOMICS INC.
COFACTOR GENOMICS INC.
COOPER SURGICAL INC.
CORIELL LIFE SCIENCES INC.
CORRELAGEN DIAGNOSTICS INC.
COURTAGEN LIFE SCIENCES INC.
CYNVENIO BIOSYSTEMS INC.
CYPHER GENOMICS INC.
DARUI BIOTECHNOLOGY CO. LTD.
DIRECTED GENOMICS LLC
DNA ELECTRONICS LTD.
EXACT SCIENCES CORPORATION
EXOSOME DIAGNOSTICS INC.
FOUNDATION MEDICINE INC.
FULL GENOMES CORPORATION
FUSION GENOMICS CORPORATION
GATC BIOTECH AG
GENE BY GENE LTD.
GENOMATIX SOFTWARE GMBH
GENOME.ONE PTY LTD
GENOMIC HEALTH INC.
GENOME PROFILING LLC.
GOOD START GENETICS INC.
GRANDOMICS BIOSCIENCES CO. LTD.
GUARDANT HEALTH INC.
HELIX OPCO LLC
HTG MOLECULAR DIAGNOSTICS INC.
HUMAN LONGEVITY INC.
INEX INNOVATIONS EXCHANGE PTE LTD
INTERPACE DIAGNOSTICS LLC.
KEW GROUP INC.
KINGMED DIAGNOSTICS CENTER CO. LTD.
LABORATORY CORPORATION OF AMERICA INC.
LABORATORY FOR MOLECULAR MEDICINE
LEUCINE RICH BIO PVT. LTD.
MAVERIX BIOMICS INC.
MAYO MEDICAL LABORATORIES
MEDGENOME LABS PVT. LTD.
MOLECULAR HEALTH GMBH
MRIGLOBAL RESEARCH INSTITUTE
MYRIAD GENETICS INC.
NANOSTRING TECHNOLOGIES INC.
NEW ENGLAND BIOLABS
NEW ONCOLOGY GMBH
NUGEN TECHNOLOGIES INC.
OMIXON BIOCOMPUTING KFT
OXFORD GENE TECHNOLOGY
OXFORD NANOPORE TECHNOLOGIES LTD.
PACIFIC BIOSCIENCES OF CALIFORNIA INC.
PARADIGM DIAGNOSTICS INC
PARSEQ LAB S.R.O.
PATHWAY GENOMICS CORPORATION
PERSONAL GENOME DIAGNOSTICS INC.
POPULATION GENETICS TECHNOLOGIES LTD.
PORTABLE GENOMICS LLC
PREMAITHA HEALTH PLC
PRESSURE BIOSCIENCES INC.
QUANTUM BIOSYSTEMS INC.
QUEST DIAGNOSTICS INC.
REAL TIME GENOMICS INC.
RESOLUTION BIOSCIENCE INC.
ROCHE HOLDING AG
SEVEN BRIDGES GENOMICS INC.
SISTEMAS GENOMICOS SL
STATION X INC.
STRAND LIFE SCIENCES PVT. LTD.
STRATEC BIOMEDICAL AG
STRATOS GENOMICS INC.
SUPRATECH MICROPATH LABORATORY & RESEARCH INSTITUTE PVT. LTD.
SURE GENOMICS INC.
THERMO FISHER SCIENTIFIC INC.
TWO PORE GUYS INC.
UBIQUITY GENOMICS INC.
WAFERGEN BIO-SYSTEMS INC.
WARP DRIVE BIO LLC.
XCELL BIOSCIENCES INC.
YIKON GENOMICS CO. LTD.
ZHEJIANG DIAN DIAGNOSTICS CO. LTD.
ZIXIN PHARMACEUTICAL INDUSTRIAL CO, LTD.
ZS GENETICS INC.
Trends Market Research Â© Copyright 2019. All Rights Reserved.